Norda ASA

Equities

NORD

NO0010285190

Biotechnology & Medical Research

End-of-day quote Norwegian OTC Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
41 ^NOK	0.00%		0.00%	0.00%

2023	Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2022	Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021	CI

Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021

June 15, 2022

Norda ASA reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was NOK 139.32 million compared to NOK 469.05 million a year ago. Net income was NOK 82.14 million compared to NOK 427.66 million a year ago.

Latest news about Norda ASA

Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2022	Oct. 31	CI
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-15	CI
Norda Asa Reports Earnings Results for the Full Year Ended December 31, 2020	21-06-20	CI
Norda ASA Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2013	13-05-22	CI
Norda ASA Reports Unaudited Net Debt Results as of December 31, 2012	13-04-09	CI
Norda ASA Appoints Scient Frode Westvold as CEO	13-04-09	CI
Norda ASA Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2012	13-02-28	CI
Norda ASA Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012	12-10-31	CI
Norda ASA Obtains NOK 35 Million Line of Credit from a Norwegian Bank	12-10-12	CI
Norda ASA Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	12-08-29	CI
NorDiag ASA will Change its Name to Norda ASA	12-07-04	CI
NorDiag ASA's Equity Buyback has expired	12-06-21	CI
A family acquired 20.8% stake in NorDiag ASA (OB:NORD).	12-06-01	CI
NorDiag ASA Announces Management Changes	12-05-30	CI
NorDiag ASA Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012	12-05-24	CI
NorDiag ASA Auditor Raises 'Going Concern' Doubt	12-04-27	CI
NorDiag ASA Reports Earnings Results for the Year Ended December 31, 2011	12-04-27	CI
Tranche Update on NorDiag ASA's Equity Buyback Plan announced on May 9, 2011.	12-04-27	CI
NorDiag ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011	12-02-16	CI
NorDiag ASA and Xiril AG to Launch the Bullet Pro an Advanced High Throughput Sample Preparation Instrument	12-02-15	CI

Chart Norda ASA

Duration

Period

More charts

Company Profile

Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Companyâs products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
NORDA ASA	0.00%	18.54M
EXACT SCIENCES CORPORATION	-20.55%	10.81B
IOVANCE BIOTHERAPEUTICS, INC.	+47.97%	3.36B
GUARDANT HEALTH, INC.	-32.75%	2.22B
BGI GENOMICS CO., LTD.	-14.15%	2.16B
VERACYTE, INC.	-26.06%	1.55B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+19.85%	1.04B
SEEGENE, INC.	-2.62%	746M
CAREDX, INC	-31.67%	425M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-43.88%	405M

Bio Diagnostics & Testing